Lyell Immunopharma shareholders elect three directors, ratify EY, approve say-on-pay at 2026 annual meeting

Lyell Immunopharma, Inc.

Quorum of 67.31% (15,706,826 shares) present; all three proposals passed.
Elected Class II directors Richard Klausner, Otis Brawley, William Rieflin with >99.2% of votes cast in favor each.
Ratified Ernst & Young as independent auditor for FY2026: 15,674,347 for, 30,758 against, 1,721 abstain.
Advisory vote on named executive officer compensation passed: 11,860,218 for, 6,613 against, 410,709 abstain, 3,429,286 broker non-votes.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Lyell Immunopharma, Inc. shareholders approved Advisory vote on the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement at the 2026-06-10 meeting.

Proposal: say on pay
Outcome: passed
Meeting: 2026-06-10

Exact text from the filing

To approve, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement. The voting results were as follows: Votes For Votes Against Abstentions Broker Non-Votes Total 11,860,218 6,613 410,709 3,429,286 15,706,826

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Lyell Immunopharma, Inc. shareholders approved Election of Class II directors to hold office until the Company's 2029 annual meeting of stockholders at the 2026-06-10 meeting.

Proposal: director election
Outcome: passed
Meeting: 2026-06-10

Exact text from the filing

To elect the following Class II directors to hold office until the Company’s 2029 annual meeting of stockholders. The voting results were as follows: Name Votes For Votes Withheld Broker Non-Votes Total Richard Klausner, M.D. 12,177,913 99,627 3,429,286 15,706,826 Otis Brawley, M.D. 11,866,210 411,330 3,429,286 15,706,826 William Rieflin 12,192,547 84,993 3,429,286 15,706,826

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Lyell Immunopharma, Inc. shareholders approved Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-06-10 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2026-06-10

Exact text from the filing

To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The voting results were as follows: Votes For Votes Against Abstentions Total 15,674,347 30,758 1,721 15,706,826

View on SEC.gov

1639 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Lyell Immunopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-271071

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.